Trial · NCT05327556
Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial
NCT05327556, Phase 2, Terminated, Boston Children's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial. Trials, record NCT05327556. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05327556
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial
- NCT number
- NCT05327556
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Boston Children's Hospital
- Conditions
- Hypotension
- Interventions
- Epinephrine 0.5 mcg/kg, Epinephrine 1 mcg/kg
- First posted
- 2022-04-14
- Last updated
- 2026-07-07
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Systolic Blood Pressure | 5 minutes prior to study drug through 5 minutes after study drug | The change in SBP from the nadir SBP prior to study drug administration to the peak SBP after study drug. The nadir SBP was defined as the lowest measurement within the 5 minutes prior to or up to 1 minute after the documented time of study drug. The peak SBP was the highest measurement with 5 minutes following study drug occurring after the nadir SBP. If an additional dose of epinephrine was administered within 5 minutes of the initial dose, the timeframe was truncated so that the peak SBP was the highest value recorded prior to the subsequent epinephrine dose. |
| Secondary | Incidence of Severe (Stage II) Hypertension | 5 minutes after study drug | The proportion of patients whose peak systolic blood pressure (determined as per the primary outcome) is greater than or equal to the 95th percentile plus 12 mmHg or greater than or equal to 140 mmHg, whichever is lower. |
| Other | Incidence of Cardiac Arrest | 0 to 120 minutes after study drug | The proportion of patients who receive chest compressions at anytime from 0 to 120 minutes after the first dose of study drug |
| Other | Incidence of Extra-corporeal Membrane Oxygenation (ECMO) | 0 to 120 minutes after study drug | The proportion of patients who are cannulated to ECMO at anytime from 0 to 120 minutes after the first dose of study drug, starting at time of first flow |
| Other | Event Survival | through 120 minutes after study drug | The proportion of patients alive 120 minutes after study drug was administered. |
| Other | Survival to Hospital Discharge | through hospital discharge, truncated at 90 days | The proportion of patients alive at time of discharge from the hospital (Truncated at 90 days) |
| Other | Change in Heart Rate (HR) | 5 minutes prior to study drug through 5 minutes after study drug | The change in HR from the nadir HR prior to study drug administration to the peak HR after study drug. The nadir HR was defined as the lowest measurement within the 5 minutes prior to or up to 1 minute after the documented time of study drug. The peak HR was the highest measurement with 5 minutes following study drug occurring after the nadir HR. If an additional dose of epinephrine was administered within 5 minutes of the initial dose, the timeframe was truncated so that the peak HR was the highest value recorded prior to the subsequent epinephrine dose. |
| Other | Change in Mean Arterial Pressure (MAP) | 5 minutes prior to study drug through 5 minutes after study drug | Difference in MAP within 5 minutes before and after study drug using measurements corresponding with the nadir and peak SBP (primary outcome). |
| Other | Change in Diastolic Blood Pressure (DBP) | 5 minutes before study drug through 5 minutes after study drug | Difference in DBP within 5 minutes before and after study drug using measurements corresponding with the nadir and peak SBP (primary outcome). |
| Other | Percent Change in SBP | 5 minutes before study drug through 5 minutes after study drug | The difference in SBP before and after study drug as defined by the primary outcome, expressed as a percentage. This was calculated by dividing the change in SBP (peak SBP minus nadir SBP) by the nadir SBP. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29526678 | BACKGROUND |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23HL148312 | Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial | ROSS, CATHERINE | BOSTON CHILDREN'S HOSPITAL | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2020 to 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05327556
GET https://conductscience.org/api/trials/v1/NCT05327556/registered